蛋白质翻译重编程在肿瘤中的研究进展

doi:10.16352/j.issn.1001-6325.2024.12.1736

基础医学与临床 ›› 2024, Vol. 44 ›› Issue (12): 1736-1740.doi: 10.16352/j.issn.1001-6325.2024.12.1736

蛋白质翻译重编程在肿瘤中的研究进展

范颖^1,2, 刘洋², 刘雁勇^1,2*

1.西藏大学医学院,西藏拉萨 850000;
2.中国医学科学院基础医学研究所北京协和医学院基础学院药理学系,北京 100005

收稿日期:2024-09-20 修回日期:2024-10-14 出版日期:2024-12-05 发布日期:2024-11-26
通讯作者: ^*yanyongliu@ibms.pumc.edu.cn
基金资助:
中国医学科学院医学与健康科技创新工程(2021-I2M-1-026)

Research progress on protein translational reprogramming in tumors

FAN Ying^1,2, LIU Yang², LIU Yanyong^1,2*

1. Medical College, Tibet University, Lasa 850000;
2. Department of Pharmacology, Institute of Basic Medical Sciences CAMS,School of Basic Medicine PUMC,Beijing 100005,China

Received:2024-09-20 Revised:2024-10-14 Online:2024-12-05 Published:2024-11-26
Contact: ^*yanyongliu@ibms.pumc.edu.cn

摘要/Abstract

摘要： 蛋白质翻译重编程是细胞在应对各种刺激时做出的重要代偿性改变,使细胞蛋白质组发生快速、特异性的变化。肿瘤细胞通过内部核糖体进入位点(IRES)、非帽依赖性翻译增强子(CITE)及N6-甲基腺苷(m⁶A)修饰等机制调控蛋白质翻译重编程,这在肿瘤的发生、进展与治疗抵抗过程中发挥重要作用。深入研究蛋白质翻译重编程在肿瘤中的作用,有望发掘新的药物靶点,为肿瘤治疗提供新的方向。

关键词: 蛋白质翻译, 翻译重编程, 上皮-间质转化, 肿瘤耐药

Abstract: Protein translational reprogramming is an important compensatory change made by cells in response to a variety of stimuli, resulting in rapid, specific changes to the cellular proteome. In tumor cells, this reprogramming is regulated through several mechanisms, including the internal ribosome entry site (IRES), cap-independent translational enhancers (CITE), and N6-methyladenosine (m6A) modifications. These processes play pivotal roles in controlling protein translational reprogramming, which is essential for tumorigenesis, progression, and treatment resistance. Further research into the function of protein translational reprogramming in tumors may reveal novel therapeutic targets and offer new avenues for cancer treatment.

Key words: protein translation, translational reprogramming, epithelial-mesenchymal transition, tumor drug resistance

中图分类号:

R730.2

范颖, 刘洋, 刘雁勇. 蛋白质翻译重编程在肿瘤中的研究进展[J]. 基础医学与临床, 2024, 44(12): 1736-1740.

FAN Ying, LIU Yang, LIU Yanyong. Research progress on protein translational reprogramming in tumors[J]. Basic & Clinical Medicine, 2024, 44(12): 1736-1740.

参考文献

[1]Jia X, He X, Huang C, et al. Protein translation: biological processes and therapeutic strategies for human diseases[J]. Signal Transduct Target Ther, 2024, 9: 44. doi: 10.1038/s41392-024-01749-9.
[2]Gao X, Jin Y, Zhu W, et al. Regulation of eukaryotic translation initiation factor 4E as a potential anticancer strategy[J]. J Med Chem, 2023, 66: 12678-12696.
[3]Panwar V, Singh A, Bhatt M, et al. Multifaceted role of mTOR (mammalian target of rapamycin) signaling pathway in human health and disease[J]. Signal Transduct Target Ther, 2023, 8: 375. doi: 10.1038/s41392-023-01608-z.
[4]Zhao Y, Li C, Zhang Y, et al. CircTMTC1 contributes to nasopharyngeal carcinoma progression through targeting miR-495-MET-eIF4G1 translational regulation axis[J]. Cell Death Dis, 2022, 13: 250. doi: 10.1038/s41419-022-04686-z.
[5]Zhu Y, Xiao B, Liu M, et al. N6-methyladenosine-modified oncofetal lncRNA MIR4435-2HG contributed to stemness features of hepatocellular carcinoma cells by regulating rRNA 2'-O methylation[J]. Cell Mol Biol Lett, 2023, 28: 89. doi: 10.1186/s11658-023-00493-2.
[6]Yeh DW, Zhao X, Siddique HR, et al. MSI2 promotes translation of multiple IRES-containing oncogenes and virus to induce self-renewal of tumor initiating stem-like cells[J]. Cell Death Discov, 2023, 9: 141. doi: 10.1038/s41420-023-01427-9.
[7]Kampen KR, Sulima SO, Verbelen B, et al. The ribosomal RPL10 R98S mutation drives IRES-dependent BCL-2 translation in T-ALL[J]. Leukemia, 2019, 33: 319-332.
[8]Ryan CS, Schröder M. The human DEAD-box helicase DDX3X as a regulator of mRNA translation[J]. Front Cell Dev Biol, 2022, 10: 1033684. doi: 10.3389/fcell.2022.1033684.
[9]Benboubker V, Boivin F, Dalle S, et al. Cancer cell phenotype plasticity as a driver of immune escape in melano-ma[J]. Front Immunol, 2022, 13: 873116. doi: 10.3389/fimmu.2022.873116.
[10]Dinh NTM, Nguyen TM, Park MK, et al. Y-Box binding protein 1: unraveling the multifaceted role in cancer development and therapeutic potential[J]. Int J Mol Sci, 2024, 25:717. doi: 10.3390/ijms25020717.
[11]Kovalski JR, Kuzuoglu-Ozturk D, Ruggero D. Protein synthesis control in cancer: selectivity and therapeutic targeting[J]. EMBO J, 2022, 41: e109823. doi: 10.15252/embj.2021109823.
[12]Zhang H, Zhou J, Li J, et al. N6-methyladenosine promotes translation of VEGFA to accelerate angiogenesis in lung cancer[J]. Cancer Res, 2023, 83: 2208-2225.
[13]Robichaud N, Hsu BE, Istomine R, et al. Translational control in the tumor microenvironment promotes lung metastasis: phosphorylation of eIF4E in neutrophils[J]. Proc Natl Acad Sci USA, 2018, 115: e2202-e2209.
[14]Wu C, Wang S, Cao T, et al. Newly discovered mechanisms that mediate tumorigenesis and tumour progression: circRNA-encoded proteins[J]. J Cell Mol Med, 2023, 27: 1609-1620.
[15]Fabbri L, Chakraborty A, Robert C, et al. The plasticity of mRNA translation during cancer progression and therapy resistance[J]. Nat Rev Cancer, 2021, 21: 558-577.
[16]Xue C, Gu X, Li G, et al. Expression and functional roles of eukaryotic initiation factor 4A family proteins in human cancers[J]. Front Cell Dev Biol, 2021, 9: 711965. doi: 10.3389/fcell.2021.711965.
[17]Zindy P, Bergé Y, Allal B, et al. Formation of the eIF4F translation-initiation complex determines sensitivity to anticancer drugs targeting the EGFR and HER2 receptors[J]. Cancer Res, 2011, 71: 4068-4073.
[18]Biswas B, Guemiri R, Cadix M, et al. Differential effects on the translation of immune-related alternatively polyadenylated mRNAs in melanoma and T cells by eIF4A inhibition[J]. Cancers, 2022, 14:1177. doi: 10.3390/cancers14051177.
[19]Marafie SK, Al-Mulla F, Abubaker J. mTOR: its critical role in metabolic diseases, cancer, and the aging process[J]. Int J Mol Sci, 2024, 25. doi: 10.3390/ijms25116141.
[20]Coleman N, Stephen B, Fu S, et al. Phase Ⅰ study of sapanisertib (CB-228/TAK-228/MLN0128) in combin-ation with ziv-aflibercept in patients with advanced solid tumors[J]. Cancer Med, 2024, 13: e6877. doi: 10.1002/cam4.6877.
[21]Chen X, An Y, Tan M, et al. Biological functions and research progress of eIF4E[J]. Front Oncol, 2023, 13: 1076855. doi: 10.3389/fonc.2023.1076855.
[22]Duffy AG, Makarova-Rusher OV, Ulahannan SV, et al. Modulation of tumor eIF4E by antisense inhibition: a phase Ⅰ/Ⅱ translational clinical trial of ISIS 183750-an antisense oligonucleotide against eIF4E-in combination with irinotecan in solid tumors and irinotecan-refractory colorectal cancer[J]. Int J Cancer, 2016, 139: 1648-1657.
[23]Fang C, Xie H, Zhao J, et al. eIF4E-eIF4G complex inhibition synergistically enhances the effect of sorafenib in hepatocellular carcinoma[J]. Anticancer Drug, 2021, 32: 822-828.
[24]Nishida Y, Zhao R, Heese LE, et al. Inhibition of translation initiation factor eIF4a inactivates heat shock factor 1 (HSF1) and exerts anti-leukemia activity in AML[J]. Leukemia, 2021, 35: 2469-2481.
[25]Kayastha F, Herrington NB, Kapadia B, et al. Novel eIF4A1 inhibitors with anti-tumor activity in lymphoma[J]. Mol Med, 2022, 28: 101. doi: 10.1186/s10020-022-00534-0.

蛋白质翻译重编程在肿瘤中的研究进展

Research progress on protein translational reprogramming in tumors

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 5

编辑推荐

Metrics

本文评价

[1]	吴娜, 王东, 李京敏, 白咸勇. 羟基红花黄色素A抑制人肝癌细胞系Huh7发生上皮-间质转化[J]. 基础医学与临床, 2021, 41(10): 1423-1427.
[2]	金海丹周宪春张松男林贞花金铁峰. Mortalin促进人乳腺癌细胞MDA-MB231的恶性进展[J]. 基础医学与临床, 2015, 35(6): 833-835.
[3]	崔虎哲王申桐金铁峰周宪春元奎昌张松男. TSA体外抑制人肺癌细胞系A549细胞增殖及机制[J]. 基础医学与临床, 2014, 34(9): 1189-1192.
[4]	许力凡张记田志强吴玉章. 肿瘤抗药性的表观遗传学调控机制[J]. 基础医学与临床, 2013, 33(12): 1638-1641.
[5]	王辉张义军陈伟娟李文通李莎莎丁保清. SNAIL诱导MCF-7细胞上皮间质转化致阿霉素耐药性增加[J]. 基础医学与临床, 2010, 30(10): 1041-1045.